Jefferson University Hospitals

Physician Profile

Jean Hoffman-Censits, MD

Jefferson University Physician

Academic Title: Assistant Professor
Director, Multidisciplinary Genitourinary Oncology Center

Specialties
Medical Oncology
Medical Oncology - Bladder Cancer
Medical Oncology - Kidney Cancer
Medical Oncology - Penile Cancer
Medical Oncology - Prostate Cancer
Medical Oncology - Testicular Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697

Medical Services

Board Certifications

  • Internal Medicine
  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Education

  • Jefferson Medical College, Medical School

Residency

  • Thomas Jefferson University Hospital

Fellowship

  • Fox Chase Cancer Center

Recent Publications

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: Patient selection and special considerations

Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies

A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report

Combination immunotherapy in genitourinary malignancies

Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

Systemic chemotherapy for upper tract urothelial cancer

Perioperative and Maintenance Therapy after First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

Practical guide to the use of enzalutamide

Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye

Chemotherapy and targeted therapies: Are we making progress in castrate-resistant prostate cancer?

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group